ReviewTrends in molecular medicine2007
Fast, hungry and unstable: finding the Achilles' heel of small-cell lung cancer.
Review in Trends in molecular medicine, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Results from a biomarker study to accompany a phase II trial of RRx-001 with reintroduced platinum-based chemotherapy in relapsed small cell carcinoma.Expert opinion on investigational drugs · 2021Trial
- Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2008Trial
- Data-driven structural analysis of small cell lung cancer transcription factor network suggests potential subtype regulators and transition pathways.NPJ systems biology and applications · 2023Article
- Landscape of transcriptional deregulation in lung cancer.BMC genomics · 2018Article
- No room for statins in the quest for survival benefits in small cell lung cancer.Translational lung cancer research · 2018Article
- Anthrax toxin receptor 1 is the cellular receptor for Seneca Valley virus.The Journal of clinical investigation · 2017Article
- Treatment of limited disease small cell lung cancer: the multidisciplinary team.The European respiratory journal · 2017Review
- Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer.Cancer research · 2017Article
- Impact of MET inhibition on small-cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway.Cancer science · 2017Article
- Novel Hybrid Phenotype Revealed in Small Cell Lung Cancer by a Transcription Factor Network Model That Can Explain Tumor Heterogeneity.Cancer research · 2017Article
- Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases.Theranostics · 2017Review
- Cellular and molecular biology of small cell lung cancer: an overview.Translational lung cancer research · 2016Review
- DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2.Oncogene · 2015Article
- New metastatic model of human small-cell lung cancer by orthotopic transplantation in mice.Cancer science · 2015Article
- NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.Journal of the National Comprehensive Cancer Network : JNCCN · 2014Article
- An innocent appearing subcutaneous nodule diagnoses a small cell lung cancer in a never-smoker female.Case reports in oncological medicine · 2014Article
- Decoding ubiquitin for mitosis.Genes & cancer · 2012Article
- Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer.Nature genetics · 2012Article
- D-glucuronyl C5-epimerase suppresses small-cell lung cancer cell proliferation in vitro and tumour growth in vivo.British journal of cancer · 2011Article
- Bcl-2 and β1-integrin predict survival in a tissue microarray of small cell lung cancer.British journal of cancer · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Over 95% of patients with small-cell lung cancer (SCLC) die within five years of diagnosis. The standard of care and the dismal prognosis for this disease have not changed significantly over the past 25 years. Some of the characteristics of SCLC that have defined it as a particularly virulent form of cancer -- rapid proliferation, excessive metabolic and angiogenic dependence, apoptotic imbalance and genetic instability -- are now being pursued as tumor-specific targets for intervention both in preclinical and early phase clinical studies. Here, we summarize areas of ongoing anti-cancer drug development, including classes of agents that target essential pathways regulating proliferation, angiogenesis, apoptotic resistance, chromosomal and protein stability, and cell-cell and cell-matrix interaction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.